Seroflo Quiz

Seroflo Asthma Medication Overview

• Seroflo is indicated for the regular treatment of asthma in patients aged 12 and above, particularly for uncontrolled asthmatic patients starting from step 3.
• It is also used as maintenance treatment for well-controlled or partially controlled asthmatic patients.
• The mechanism of action involves the synthetic corticosteroid fluticasone propionate, which has anti-inflammatory activity mediated via glucocorticoid receptors and inhibition of cytokine formation.
• Additionally, it contains a highly selective β2-adrenoceptor (LABA) agonist, salmeterol, which provides long-acting bronchodilator activity through the relaxation of bronchial smooth muscle.
• Seroflo aims to improve patients' lives and achieve total control as defined by GINA guidelines, as well as improve lung function to enable engagement in everyday activities without limitations.
• A 1-year study involving 3,421 patients with uncontrolled asthma compared fluticasone propionate and salmeterol/fluticasone in achieving guideline-based measures of control, with treatment stepped up until total control was achieved.
• The study design included a stratified, randomized, double-blind, parallel-group study, with the largest number of patients ever recruited in a trial on asthma.
• Another concept study aimed to assess the effectiveness of Seroflo in adult patients with symptomatic asthma not controlled by existing therapy, involving a 52-week double-blind treatment period and a 2-week follow-up period.
• The double-blind treatment period involved two phases, the first maintaining a constant dose delivered from both devices, and the second adjusting the dose delivered via Turbuhaler according to physician guidance.
• The device used for Seroflo, Ciphaler, ensures high compliance and dose delivery, with a well-known inhaler design and the addition of a dose counter to ensure compliance.
• Seroflo's benefits include improving patients' lives, helping them lead healthier, happier, and more fulfilling lifestyles, achieving total control as per GINA guidelines, and improving lung function to enable engagement in everyday activities without limitations.
• The GINA guidelines provide specific recommendations for asthma management in children and adults, including the use of anti-inflammatory reliever (AIR) and guidelines for asthma severity and control assessment.